Skip to main content


Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Everolimus-eluting bioresorbable scaffolds for treatment of coronary artery disease in patients with diabetes mellitus: the midterm follow-up of the prospective ABSORB DM Benelux study

Fig. 1

Kaplan–Meier estimates with 95% confidence intervals of a major adverse cardiac events, b target lesion failure, c definite or probable scaffold thrombosis at 2-year follow-up. MACE major adverse cardiac events, TLF target lesion failure, ScT scaffold thrombosis, KM est Kaplan–Meier estimate, CI confidence interval

Back to article page